No abstract available.
Hyperamylasemia*

No abstract available.
Hyperamylasemia* ; Sertraline*

Acute pancreatitis as a complication of organophosphate intoxication has been infrequently addressed. Previous reports have suggested that acute pancreatitis may follow the oral ingestion of several organophosphates. The pathogenesis of this pancreatic damage has been studied in a few animal studies. However, the association between acute pancreatits and human organophosphate intoxication may still not be widely recognized. We experienced 6 cases described as hyperamylasemia and hyperlipasemia with a presumptive diagnosis of acute pancreatitis following organophosphate intoxication, and we analyzed them to provide human baseline data for further studies and patient management. We report these case series with an analysis and a literature review.
Animals ; Diagnosis ; Eating ; Humans ; Hyperamylasemia ; Organophosphates ; Pancreatitis*

There is growing evidence that oxygen-derived free radicals(OFR's) play a role in the pathogenesis of pancreatic diseases, especially of acute pancreatitis. Many types of experimental ex vivo and in vitro pancreatitis can be inhibited by superoxide dismutase and catalse. (continue...)
Hyperamylasemia* ; Oxygen* ; Pancreatic Diseases ; Pancreatitis ; Superoxide Dismutase

Humans ; Hyperamylasemia ; physiopathology ; Infant, Newborn ; Neonatology

For many years ERCP has been contraindicated in acute pancreatitis. The injection of contrast medium. which may cause hyperamylasemia and occasionally an attack of acute pancreatitis even in normal indivisuals, was allowed only two to three weeks after subsidence of symptoms. Gallstone disease is one of the most common etilogical factors in pancreatitis and migration or impaction of gallstone in the ampulla of Vater causes pancreatitis. (continue...)
Ampulla of Vater ; Cholangiopancreatography, Endoscopic Retrograde* ; Gallstones ; Hyperamylasemia ; Pancreatitis*

PURPOSE: Postoperative hyperamylasemia and pancreatitis may sometimes follow abdominal surgery but the significance and cause of hyperamylasemia after colorectal surgery were not studied enoughly. Our study was designed to identify the incidence of hyperamylasemia after colorectal surgery, to investigate the effect of hyperamylasemia on postoperative hospital course, and to clarify the causes such as extent of colorectal resection or intraoperative events. METHODS: The serum amylase was determined in post operative first day in random sampled 72 patient among whom underwent elective colorectal resection from March 2000 to July 2001. If a hyperamylasemia was evident, repeated check the level till it returned to within normal range. Other factors that seemed to affect serum amylase such as traction of pancreas during operative manupulation, intraoperative hypotensive episode or infused drug and volume expanders etc. were reviewed and analysed. RESULTS: Hyperamylasemia occurred in 25 patients (34.7%) after colorectal surgery. Serum amylse level returned to normal in all but nine patients (12.4%) by third postoperative day, two patients (2.8%) by the fifth postoperative day. Pancreas manupulation and intraoperative use of volume expander, amylopectin were found to be significantly associated with postoperative hyperamylasemia by 2-test and pearson correlation analysis. The developement of hyperamylasemia did not adversely influence the postoperative hospital course. CONCLUSIONS: Twenty-five (34.7%) in seventy-two patients who underwent colorectal surgery developed hyperamylasemia after operation. The incidence was significantly high in a group who underwent surgical procedure with more pancreas manupulation and infused hydroxyethyl starch (amylopectin) containing volume expander. The development of postoperative hyperamylasemia did not seem to influence adversely the postoperative hospital course in this study.
Amylases ; Amylopectin ; Colorectal Surgery* ; Humans ; Hyperamylasemia* ; Incidence ; Pancreas ; Pancreatitis ; Reference Values ; Starch ; Traction

Macroenzymes are high molecular weight complexes formed in the serum by self-polymerization or by association with other proteins. Macroenzymes are filtered with difficulty by normal renal glomeruli. Clinically, it is important to detect macroenzymes, because they frequently interfere with the interpretation of serum enzyme results, and as a result they can cause diagnostic and therapeutic errors. Macroamylasemia and macrolipasemia have been found to occur in apparently healthy humans, as well as in a variety of disease states, including liver disease, diabetes, cancer, malabsorption, and autoimmune disorders. We report a patient with alcoholic liver cirrhosis and macroamylasemia and macrolipasemia, the latter two of which were discovered using a screening test.
Alcoholics ; Humans ; Hyperamylasemia ; Liver Cirrhosis ; Liver Cirrhosis, Alcoholic ; Liver Diseases ; Mass Screening ; Molecular Weight ; Proteins

The trans-sphenoidal resection of a recurred pituitary tumor was performed in a 42 years old man under general anesthesia with propofol and remifentanil. Neither massive bleeding nor hypotension was observed intraoperatively, but bradycardia was sustained over five hours. The patient did not suffer from hypertriglyceridemia and there was no evidence of drug toxicity or vigorous intervention during the surgery, however hyperamylasemia was observed one day after the surgery. It is presumed that vagal stimulation by propofol and remifentanil infusion might induce bradycardia and abnormal pancreatic enzyme secretion consequently.
Anesthesia, General ; Bradycardia ; Drug Toxicity ; Hemorrhage ; Humans ; Hyperamylasemia ; Hypertriglyceridemia ; Hypotension ; Piperidines ; Pituitary Neoplasms ; Propofol

BACKGROUND/AIMS: The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to endoscopic retrograde cholangiopancreatography (ERCP). In vitro, nafamostat inhibits the pancreatic protease activities 10-100 times more potently than gabexate. We evaluated the efficacy of nafamostat for prophylaxis against post-ERCP pancreatitis in comparison with gabexate. METHODS: Five hundred patients (208 patients in the nafamostat-treated group and 292 in the gabexate-treated group) were analyzed retrospectively after selective exclusion. The incidences of pancreatitis and hyperamylasemia after the ERCP were compared between the nafamostat and gabexate groups. RESULTS: The incidences of acute pancreatitis and hyperamylasemia were 9.1% and 40.9%, respectively, in the nafamostat-treated group, and 8.6% and 39.4% in the gabexate-treated group. The frequencies of post-ERCP pancreatitis and hyperamylasemia did not differ significantly between the two groups, Post-ERCP pancreatitis in two group did not vary according to the different ERCP procedures. The mean serum amylase level at 6 h after ERCP was significantly lower in the nafamostat-treated group than in the gabexate-treated group (p=0.020). However, the difference in serum amylase level did not persist at 18 h and 36 h post-ERCP. CONCLUSIONS: Administration of nafamostat before ERCP was not inferior to gabexate in protecting against the development of pancreatitis.
Amylases ; Cholangiopancreatography, Endoscopic Retrograde ; Gabexate ; Guanidines ; Humans ; Hyperamylasemia ; Incidence ; Pancreatitis ; Protease Inhibitors ; Retrospective Studies